The funding will help the San Francisco-based firm apply low-depth NGS as it builds diagnostic tests to aid therapy selection in more diverse populations.
Under the agreement, Israel’s BiomX will generate metagenomic data for gut microbiome samples from IBD patients using its XMarker biomarker discovery platform.
With single-cell transcriptomic, T cell receptor, and B cell receptor data, researchers tracked immune shifts in tissue and peripheral blood samples from ulcerative colitis patients.
The companies will jointly validate novel drug targets identified by Scipher's molecular interaction network platform for patients with inflammatory bowel disease.
Based in Boston with operations in Ireland and Iceland, the reorganized company is supporting COVID-19 testing and population genomics as it sheds its China division.
The company will apply its single-cell RNA-seq analytics technology to three distinct cohorts in pursuit of new drug targets for inflammatory bowel disease.
Second Genome will use its Microbiome Analytics platform to identify novel biomarkers linked to clinical responses to Gilead's investigational medicines.
Under the deal, KSL will commercialize and facilitate orders of the PredictSURE IBD test throughout North America and will also process all samples through its laboratory, KSL Diagnostics.
